These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 14578466

  • 1. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
    Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK.
    Mol Cancer Ther; 2003 Oct; 2(10):1011-21. PubMed ID: 14578466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 5. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 01; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.
    Breast; 2013 Aug 01; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 13. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.
    Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP, Taguchi H.
    Cancer Sci; 2006 Sep 01; 97(9):945-51. PubMed ID: 16916320
    [Abstract] [Full Text] [Related]

  • 14. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
    Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD.
    J Pharmacol Exp Ther; 2003 Nov 01; 307(2):476-80. PubMed ID: 12966161
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):229-35. PubMed ID: 17089166
    [Abstract] [Full Text] [Related]

  • 16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
    Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.
    Invest New Drugs; 2011 Dec 01; 29(6):1123-31. PubMed ID: 20467883
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
    Schem C, Bauerschlag D, Bender S, Lorenzen AC, Loermann D, Hamann S, Rösel F, Kalthoff H, Glüer CC, Jonat W, Tiwari S.
    BMC Cancer; 2013 Jan 24; 13():32. PubMed ID: 23347638
    [Abstract] [Full Text] [Related]

  • 19. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 20. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F.
    Clin Cancer Res; 2005 Aug 15; 11(16):5827-32. PubMed ID: 16115922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.